Cancer Treatment

A hormone-blocking pill approved last year for some men with advanced prostate cancer now also seems to help a wider group of men who were given it sooner in the course of treating their disease. In a study of nearly 1,100 such men, Johnson & Johnson's Zytiga doubled the time patients lived without their cancer getting worse.

A  new drug for advanced prostate cancer patients has proved so effective that scientists stopped the clinical trial early to give all patients a chance to receive the life-extending medication, according to a UCSF-led study.

The hormone treatment, Johnson & Johnson's Zytiga, when added to a standard steroid therapy doubled the time it takes for the disease to progress in patients treated with the standard therapy alone, said the lead researcher, Dr. Charles Ryan, associate professor of clinical medicine at the UCSF Helen Diller Family Comprehensive Cancer Center.

The U.S. Food and Drug Administration last year approved Zytiga, also known as abiraterone, for use in men whose prostate cancer had spread to other parts of their body and had already been treated with chemotherapy. The FDA will have to approve it for patients who have not had chemotherapy before it can be marketed for broader use.

This trial focused on patients whose cancer had metastasized, may have been treated with other hormone therapies but had not yet gone through chemotherapy. The interim results are to be presented Saturday at the American Society of Clinical Oncology's annual meeting in Chicago.

"If the FDA looks favorably upon the data ... it will really change the standard of care in advanced prostate cancer away from chemotherapy toward a well-tolerated, oral therapy," Ryan said from Chicago. "It opens up the possibility of this life-prolonging therapy being given to a larger population of patients."

Prostate cancer, the second most common form of cancer in males after only lung cancer, is diagnosed in about 200,000 men in the United States each year. And while it is generally treatable, the disease kills nearly 30,000 men a year.

Zytiga is the first FDA-approved drug that can go inside the cancer cell and block it from making its own testosterone.

The trial involved 1,088 men who were being treated by 151 cancer centers in 12 countries. Each was given a low dose of the steroid prednisone, which works to combat the cancer, but some received Zytiga while others were given a placebo.

All participants receiving the placebo drug were allowed in March to start taking Zytiga. Not only did they notice a slowdown in the progression of the disease, but patients also reported reduced pain and went longer before having to resort to chemotherapy.

If the FDA extends Zytiga's approval to include patients who have not yet gone through chemotherapy, more health insurers will cover the drug. The final results of the trial are expected next year.

One trial participant, Michael Wells, 65, was diagnosed in 2000 with prostate cancer that had spread to his hip bone. He was treated with various hormone therapies, but the disease kept recurring.

During the trial, the Oakville resident didn't know whether he was taking the real drug or the placebo, but he guessed about a year into it that he was on Zytiga. He was tired, his blood pressure went up - a potential side effect of the drug - and his cancer stayed in check.

Wells guessed right and continues to take the drug. He was pleased but not surprised by the trial results because his disease has remained under control.

Rodolfo Chavez, 83, who was diagnosed with prostate cancer in 1997 and learned it had spread in 2006, calls Zytiga his miracle drug. Chavez, who has had chemotherapy, started taking it last year after it was approved.

"After that first bottle, my pain went away and I just felt like my life was turning around," said the former longshoreman from San Pedro (Los Angeles County). "I'm still taking them. I'm on my 10th bottle and supposed to get another bottle today."


SOURCE  San Francisco Chronicle

By 33rd Square

Subscribe to 33rd Square